Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Claims
Claims 33-39, 41-54, and 57-58 are pending in the instant application.
Claims 1-32, 40, and 55-56 have been canceled.
Withdrawn Rejections/Objections
Applicant’s amendment is sufficient to overcome the rejection of Claims 33-48 and 51-54 under 35 U.S.C. 112(a). Applicant’s cancellation of claim 40 renders the rejection thereof moot. This rejection is hereby withdrawn.
Applicant’s amendment is sufficient to overcome the rejection of Claims 33-37, 40-43, 46, and 51-52 under 35 U.S.C. 102(a)(1). Applicant’s cancellation of Claim 40 renders the rejection thereof moot. These rejections are hereby withdrawn.
The following rejections are necessitated by amendment:
Claim Rejections - 35 USC § 102
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
Claims 33-37, 41-43, 46, and 51-52 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry File (1110985-63-1, entered into STN February 24th, 2009; obtained from the internet February 2nd, 2026; hereinafter referred to as CAS Registry File 1).
CAS Registry File teaches a compound of the following formula:
PNG
media_image1.png
245
548
media_image1.png
Greyscale
This compound reads on a compound of formula (I) as recited at instant Claim 33 when the variables are defined as follows:
R1, R2, R6, and R7 are each hydrogen.
R3 is hydrogen.
R4 is hydrogen.
R5 is hydrogen.
L1 is a covalent bond.
A is phenyl.
RA1 is the group
PNG
media_image2.png
72
109
media_image2.png
Greyscale
, wherein L2 is a covalent bond, B is C2-heteroaryl, wherein C2-heteroaryl is oxadiazolyl, wherein RB1 is the group
PNG
media_image3.png
82
99
media_image3.png
Greyscale
, wherein L4 is a covalent bond, D is C3 cycloalkyl, and RD1, RD2, and RD3 are each hydrogen.
RA2 is hydrogen.
RA3 is hydrogen.
Claims 33-39, 41-43, 46, and 51-52 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry File (1111141-31-1; entered into STN February 24th, 2009; obtained from the internet February 2nd, 2026; hereinafter referred to as CAS Registry File 2).
CAS Registry File 2 teaches a compound of the following structure:
PNG
media_image4.png
230
578
media_image4.png
Greyscale
This compound reads on a compound of formula (I) as recited at instant Claim 33 when the variables are defined as follows:
R1, R2, R6, and R7 are each hydrogen.
R3 is methyl.
R4 is hydrogen.
R5 is hydrogen.
L1 is a covalent bond.
A is phenyl.
RA1 is the group
PNG
media_image2.png
72
109
media_image2.png
Greyscale
, wherein L2 is a covalent bond, B is C2-heteroaryl, wherein C2-heteroaryl is oxadiazolyl, wherein RB1 is the group
PNG
media_image3.png
82
99
media_image3.png
Greyscale
, wherein L4 is a covalent bond, D is C3 cycloalkyl, and RD1, RD2, and RD3 are each hydrogen.
RA2 is hydrogen.
RA3 is hydrogen.
Claims 33-37, 41-44, 46-47, and 51-52 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry File 1110985-61-9 (entered into STN February 24th, 2009; obtained from the internet February 2nd, 2026; hereinafter referred to as CAS Registry File 3).
CAS Registry File teaches a compound of the formula:
PNG
media_image5.png
236
528
media_image5.png
Greyscale
R1, R2, R6, and R7 are each hydrogen.
R3 is hydrogen.
R4 is hydrogen.
R5 is hydrogen.
L1 is a covalent bond.
A is phenyl.
RA1 is the group
PNG
media_image2.png
72
109
media_image2.png
Greyscale
, wherein L2 is a covalent bond, B is C2-heteroaryl, wherein C2-heteroaryl is oxadiazolyl, wherein RB1 is C3-alkyl.
RA2 is hydrogen.
RA3 is hydrogen.
Allowable Subject Matter
Claims 49-50 and 57-58 are allowed.
Claims 45, 48, and 53-54 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Conclusion
Claims 33-39, 41-44, 46-47, and 51-52 are rejected.
Claims 45, 48, and 53-54 are objected to.
Claims 49-50 and 57-58 are allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL JOHN BURKETT whose telephone number is (703)756-5390. The examiner can normally be reached Monday - Friday.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/D.J.B./Examiner, Art Unit 1624
/JEFFREY H MURRAY/Supervisory Patent Examiner, Art Unit 1624
Prosecution Insights